nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»nogr-557Research ArticleОБЗОРREVIEWСОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА, МИРОВОЙ ОПЫТ: ОБЗОР ЛИТЕРАТУРЫACTUAL CAPACITY OF TREATMENT IRRITABLE BOWEL SYNDROME, GLOBAL EXPERIENCE: REVIEW OF THE LITERATUREКрутихинаС. Б.KrutikhinaS. B.noemail@neicon.ruГореловА. В.GorelovA. V.noemail@neicon.ruПервый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет); ФБУН «Центральный НИИ эпидемиологии» РоспотребнадзораРоссияI. M. Sechenov First Moscow State Medical University; Central Research Institute of epidemiology of the Federal Servise of Customers` Right Protection and Human Well-Being SurveillanceRussian Federation20182002201802137141Copyright © Крутихина С.Б., Горелов А.В., 20182018Крутихина С.Б., Горелов А.В.Krutikhina S.B., Gorelov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/557

Синдром раздраженного кишечника (СРК) представляет собой функциональное расстройство органов пищеварения, которое проявляется абдоминальными болями и сопровождается расстройствами дефекации [2]. Распространенность СРК варьирует от 3% до 28% в различных странах [2, 4]. Патогенез СРК до сих пор не полностью ясен, и на сегодняшний день обнаружена связь с генетическими, иммунными факторами, нарушениями функционирования оси «мозг-кишечник», изменениями в микробиоте и психосоциальными факторами [3-12]. В исследованиях установлена способность кишечной микробиоты вырабатывать нейротрансмиттеры, изменяющие секрецию и моторику кишечника, а также порог висцеральной чувствительности [8, 9]. Приведены данные наблюдений в мире в целом по эффективности и безопасности применения пробиотика B. longum infantis (longum) 35624 у пациентов с СРК и некоторыми другими заболеваниями ЖКТ.

Irritable bowel syndrome (IBS) is a functional disorder of digestive organs, which manifests itself as abdominal pain and accompanied by disorders of defecation [2]. The prevalence of IBS ranges from 3% to 28% in different countries [2, 4]. The pathogenesis of IBS is still not completely clear, and now relation found with genetic, immune factors, impaired functioning axis the “brain-gut”, changes in the microbiota and psychosocial factors [3-12]. The ability of intestinal microbiota to produce neurotransmitters that change intestinal secretion and motility, as well as visceral sensitivity threshold [8, 9] was established in the studies. The data of observations in the world as a whole on the efficacy and safety of probiotic B. longum infantis (longum) 35624 in patients with IBS and some other gastrointestinal diseases.

ReferencesБельмер С.В., Хавкин А. И., Печкуров Д. В. «Функциональные расстройства органов пищеварения у детей (в свете Римских критериев IV)». Методическое пособие. Москва, 2016, с. 66-68Бельмер С.В., Хавкин А. И., Печкуров Д. В. «Функциональные расстройства органов пищеварения у детей (в свете Римских критериев IV)». Методическое пособие. Москва, 2016, с. 66-68Foxx-Orenstein A. E. “New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists”. Ther Adv Gastroenterol, 2016, Vol. 9(3) 354-375Foxx-Orenstein A. E. “New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists”. Ther Adv Gastroenterol, 2016, Vol. 9(3) 354-375Camilleri, M. “Peripheral mechanisms in irritable bowel syndrome”. N Engl J Med 2012367: 1626-1635.Camilleri, M. “Peripheral mechanisms in irritable bowel syndrome”. N Engl J Med 2012367: 1626-1635.Ek, W., Reznichenko, A., Ripke, S., et al. “Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts” (он-лайн публикация). 2015, Gut 64: 1774-1782.Ek, W., Reznichenko, A., Ripke, S., et al. “Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts” (он-лайн публикация). 2015, Gut 64: 1774-1782.Grasberger, H., Chang, L., Shih, W., Presson, A., Sayuk, G., Newberry, R. et al. (2013) Identificationof a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J. Gastroenterol 108: 1766-1774.Grasberger, H., Chang, L., Shih, W., Presson, A., Sayuk, G., Newberry, R. et al. (2013) Identificationof a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J. Gastroenterol 108: 1766-1774.Bashashati, M., Rezaei, N., Shafieyoun, A., et al. “Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis”. Neurogastroenterol Motil 2014, 26: 1036-1048.Bashashati, M., Rezaei, N., Shafieyoun, A., et al. “Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis”. Neurogastroenterol Motil 2014, 26: 1036-1048.Rana, S., Sharma, S., Sinha, S., Parsad, K., Malik, A. and Singh, K. “Pro inflammatory and anti-inflammatory cytokine response in diarrhoeapredominant irritable bowel syndrome patients”. Trop Gastroenterol, 2012, 33: 251-256.Rana, S., Sharma, S., Sinha, S., Parsad, K., Malik, A. and Singh, K. “Pro inflammatory and anti-inflammatory cytokine response in diarrhoeapredominant irritable bowel syndrome patients”. Trop Gastroenterol, 2012, 33: 251-256.Walker, M., Talley, N., Prabhakar, M., Pennaneac’h, C., Aro, P., Ronkainen, J. et al. “Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia”. Aliment Pharmacol Ther, 2009, 29: 765-773.Walker, M., Talley, N., Prabhakar, M., Pennaneac’h, C., Aro, P., Ronkainen, J. et al. “Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia”. Aliment Pharmacol Ther, 2009, 29: 765-773.Vivinus-Nebot, M., Dainese, R., Anty, R., et al. “Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells”. Am J. Gastroenterol, 2012, 107: 75-81.Vivinus-Nebot, M., Dainese, R., Anty, R., et al. “Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells”. Am J. Gastroenterol, 2012, 107: 75-81.Tornblom, H., Van, O., Sadik, R., Abrahamsson, H., Tack, J. and Simren, M. “Colonic transit time and IBS symptoms: what’s the link?” Am J Gastroenterol., 2012, 107: 754-760.Tornblom, H., Van, O., Sadik, R., Abrahamsson, H., Tack, J. and Simren, M. “Colonic transit time and IBS symptoms: what’s the link?” Am J Gastroenterol., 2012, 107: 754-760.Larsson, M., Tillisch, K., Craig, A., Engstrom, et al. “Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome». Gastroenterology, 2012, 142: 463-472.Larsson, M., Tillisch, K., Craig, A., Engstrom, et al. “Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome». Gastroenterology, 2012, 142: 463-472.Tillisch, K., Mayer, E. and Labus, J. “Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome”. Gastroenterology, 2011, 140: 91-100.Tillisch, K., Mayer, E. and Labus, J. “Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome”. Gastroenterology, 2011, 140: 91-100.Rey de Castro, N., Miller, V., Carruthers, H. and Whorwell, P. “Irritable bowel syndrome: a comparison of subtypes”. J Gastroenterol Hepatol, 2015, 30: 279-285.Rey de Castro, N., Miller, V., Carruthers, H. and Whorwell, P. “Irritable bowel syndrome: a comparison of subtypes”. J Gastroenterol Hepatol, 2015, 30: 279-285.Singh, P., Agnihotri, A., Pathak, M., Shirazi, A., et al. “Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center”. J Neurogastroenterol Motil, 201218: 324-331.Singh, P., Agnihotri, A., Pathak, M., Shirazi, A., et al. “Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center”. J Neurogastroenterol Motil, 201218: 324-331.Corsetti M. and Whorwell P. “The global impact of IBS: time to think about IBS-specific models of care?” Ther Adv Gastroenterol 2017, Vol. 10(9) 727-735.Corsetti M. and Whorwell P. “The global impact of IBS: time to think about IBS-specific models of care?” Ther Adv Gastroenterol 2017, Vol. 10(9) 727-735.Schwille-Kiuntke J, Enck P, Zendler C et al. “Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confi rmed cases of bacterial infection with Salmonella or Campylobacter”. Neurogastroenterol Motil, 2011; 23: e479-88.Schwille-Kiuntke J, Enck P, Zendler C et al. “Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confi rmed cases of bacterial infection with Salmonella or Campylobacter”. Neurogastroenterol Motil, 2011; 23: e479-88.Ringel Y, Ringel-Kulka T. “The intestinal microbiota and irritable bowel syndrome”. J Clin Gastroenterol 2015; 49: S56-9.Ringel Y, Ringel-Kulka T. “The intestinal microbiota and irritable bowel syndrome”. J Clin Gastroenterol 2015; 49: S56-9.Malinen E, Rinttila T, Kajander K, et al. “Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR”. Am J Gastroenterol, 2005; 100:373-82;Malinen E, Rinttila T, Kajander K, et al. “Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR”. Am J Gastroenterol, 2005; 100:373-82;Spiller, R.C. “Postinfectious irritable bowel syndrome” Gastroenterol., 2003.Vol. 124, No. 6. - Р. 1662-1671Spiller, R.C. “Postinfectious irritable bowel syndrome” Gastroenterol., 2003.Vol. 124, No. 6. - Р. 1662-1671Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory “T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis”. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4615-22;Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory “T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis”. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4615-22;Atarashi K, Tanoue T, Shima T. et al. “Induction of colonic regulatory T cells by indigenous Clostridium species”. Science, 2011; 331:337-41;Atarashi K, Tanoue T, Shima T. et al. “Induction of colonic regulatory T cells by indigenous Clostridium species”. Science, 2011; 331:337-41;Konieczna P, Akdis CA, Quigley EM, Shanahan F, O’Mahony L. “Portrait of an immunoregulatory Bifidobacterium”. Gut Microbes 2012; 3:261-6;Konieczna P, Akdis CA, Quigley EM, Shanahan F, O’Mahony L. “Portrait of an immunoregulatory Bifidobacterium”. Gut Microbes 2012; 3:261-6;Brenner D. M., Chey W. D. “Bifidobacterium infantis 35624: A Novel Probiotic for the Treatment of Irritable Bowel Syndrome” REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2009, Vol. 9 N. 1 рр 7-15Brenner D. M., Chey W. D. “Bifidobacterium infantis 35624: A Novel Probiotic for the Treatment of Irritable Bowel Syndrome” REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2009, Vol. 9 N. 1 рр 7-15Quigley E. M., Fried M., Gwee K.-A. et al. World Gastroenterology Organisation Global Guidelines “Irritable Bowel Syndrome: a Global Perspective” Update September 2015, рр. 17-20.Quigley E. M., Fried M., Gwee K.-A. et al. World Gastroenterology Organisation Global Guidelines “Irritable Bowel Syndrome: a Global Perspective” Update September 2015, рр. 17-20.F. Guarner, Sanders M. E., Eliakim R. World Gastroenterology Organisation Global Guidelines “Probiotics and prebiotics”, February 2017, рр 14.F. Guarner, Sanders M. E., Eliakim R. World Gastroenterology Organisation Global Guidelines “Probiotics and prebiotics”, February 2017, рр 14.McCarthy J, O’Mahony L, O’Callaghan L, et al. “Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance”. Gut.2003;52: 975-980.McCarthy J, O’Mahony L, O’Callaghan L, et al. “Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance”. Gut.2003;52: 975-980.Jobin C, Sartor RB. “The I-B/NF-B system: a key determinant of mucosal inflammation and protection”. Am J Physiol Cell Physiol. 2000;278: C451-C462.Jobin C, Sartor RB. “The I-B/NF-B system: a key determinant of mucosal inflammation and protection”. Am J Physiol Cell Physiol. 2000;278: C451-C462.O’Mahony L, McCarthy J, Kelly P, et al. “Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles”. Gastroenterology. 2005;128:541-551.O’Mahony L, McCarthy J, Kelly P, et al. “Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles”. Gastroenterology. 2005;128:541-551.Heaton KW, O’Donnell LJ. “An office guide to whole-gut transit time. Patients’ recollection of their stool form”. J Clin Gastroenterol. 1994;19:28-30.Heaton KW, O’Donnell LJ. “An office guide to whole-gut transit time. Patients’ recollection of their stool form”. J Clin Gastroenterol. 1994;19:28-30.Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590.Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590.Ringel-Kulka T., McRorie J, Ringel Y. “Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefi t of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating”. Am J Gastroenterol., 2016; doi: 10.1038/ajg.2016.511Ringel-Kulka T., McRorie J, Ringel Y. “Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefi t of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating”. Am J Gastroenterol., 2016; doi: 10.1038/ajg.2016.511Charbonneau D., Gibb R. D., Quigley E. M. “Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated Probiotic”. 2013, Gut Microbes 4:3, 201-211Charbonneau D., Gibb R. D., Quigley E. M. “Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated Probiotic”. 2013, Gut Microbes 4:3, 201-211Groeger D., O’Mahony L., Murphy E. F., Bourke J. F. et al. “Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut”. Gut Microbes, 2013,4:4, 1-15Groeger D., O’Mahony L., Murphy E. F., Bourke J. F. et al. “Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut”. Gut Microbes, 2013,4:4, 1-15Altmann F. et al. Plos one. 2016, sept 22, 11(9).Altmann F. et al. Plos one. 2016, sept 22, 11(9).

The authors declare that there are no conflicts of interest present.